valu usd unless otherwis note
view highlight continu gross order
out-performance geograph broad base overal
believ benefit strong new product portfolio
appear continu acceler radiat oncolog market
growth result rais pt
revenu exceed expect non-gaap
oper margin fell short report revenu
fce y/i rbce oncolog system revenu
fce y/i rbce proton
therapi revenu fce non-gaap ep
fce benefit lower tax rate non-
oper margin came consensu
non-gaap gross margin fce oper
expens ratio fce attribut oper
margin weak tariff astro fall fiscal year recent
 a/oth invest made unfavor geograph mix
gross order came well consensu oncolog
system gross order fce y/i rbce
repres highest growth rate decad
rbce emea y/i rbce apac y/i
rbce book halcyon order quarter vs
final proton
therapi gross order fce
book proton order
manag reiter guidanc reiter
revenu guidanc fce y/i
report rbce revenu hit tariff fx
includ guidanc manag also reiter non-
gaap ep guidanc fce guidanc continu
assum non-gaap oper margin fce
notabl impli acceler manag work
off-set tariff impact suppli chain commerci oper
action product rephas invest
radiat oncolog market growth remain strong
benefit solid new product portfolio appear radiat
oncolog gross order market growth may acceler
comment emerg market growth strong
see acceler replac cycl
china saw double-digit y/i gross order growth
meaning benefit new china quota overal believ
benefit recent radiat oncolog market pickup
best-in-class ct-base linac softwar product portfolio
allow patient front
price prior trade day market close estimate unless otherwis note
believ varian share perform line peer
group follow key reason
lead suit radiat oncolog product
medium-term world-wide radiat oncolog market
growth difficult forecast earn growth
tie manag abil grow top line
supplement modest oper leverag
order growth y/i backlog grew
growth distributor convers trend remain difficult
forecast continu us hospit consolid trend
toward hypofraction us reimburs cut
bundl initi could lead medium-term pressur
softwar servic busi appear
healthi imag compon show earli sign
revenu service/licens contribut
revenu expect grow busi
strong high-single-digit y/i go forward addit
expect busi continu drive oper
margin expans softwar gross margin
rang servic gross margin
rang compar overal oncolog
system margin
proton therapi repres growth driver still
uncertainti whether signific invest
therapi produc strong futur
proton-therapi busi begin break even
profit point view
proven clinic benefit proton therapi versu photon/
x-ray-bas linac vault size cost commerci
reimburs difficulti limit adopt
bring size cost proton therapi
system insur make proton reimburs less
favor adopt therapi may remain slow
upcom potenti catalyst event potenti
hospit capit spend
competit risk elekta slower-than-
expect ramp proton therapi radiat oncolog
reimburs risk hospitals/freestand center
on-going lawsuit fda regulatori risk surround new
systems/softwar modul risk tariff risk
bloomberg capit market estim upside/downside/target
base scenario assum share rise
share base weight averag dcf price-to-earnings ev/ebitda
assum world-wide radiat oncolog market
grow y/i varian slightli grow world-wide
oncolog system separ assum
proton therapi show mid-single-digit y/i growth
bottom line assum medium-term non-
oper margin leverag non- ep
growth howev ep growth constrain
manag assum ep headwind tariff
cost save offset
upsid scenario assum share rise
share assum world-wide radiat oncolog
market grow high-single-digit y/i varian grow
world-wide linac share model high-single-digit y/i
constant-curr growth oncolog system
separ assum proton therapi show low-double-
digit y/i growth bottom line model
non-gaap oper margin leverag
non-gaap ep growth medium-term
downsid scenario assum share fall
assum declin reimburs
bundl slow demand linac system put
pressur price also assum elekta regain
system momentum slow recent share gain
accordingli model low-single-digit y/i constant-curr
growth oncolog system separ
assum proton therapi adopt acceler
reimburs fall bottom line model
non-gaap oper margin leverag
non-gaap ep growth medium-term
stand-alone price target perform discount cash flow dcf price-to-earnings
ev/ebitda analysi come intrins valu varian share get
price target assign weight intrins valu calcul
dcf analysi weight intrins valu calcul price-to-earnings
analysi weight intrins valu calcul ev/
ebitda analysi assumpt use analysi includ follow
dcf analysi use wacc assum termin valu ev/ebitda multipl
separ assign target forward price-to-earnings multipl varian slightli
varian large-cap peer group averag target forward ev/ebitda multipl
slightli varian large-cap peer group averag believ slight
premium group averag multipl warrant given expect superior medium-
term growth rel group price target support sector perform rate
risk rate price target
risk price target rate includ slow hospit capit spend
competit risk elekta var two main oncolog system competitor
slower-than-expect ramp proton therapi market radiat oncolog
reimburs risk hospit freestand center on-going lawsuit fda
regulatori risk surround new systems/softwar modul risk tariff risk
varian headquart palo alto ca world lead manufactur medic
devic treat cancer medic condit radiotherapi radiosurgeri
proton therapi brachytherapi radiotherapi use treat head neck prostat
lung liver breast pancreat gynecolog cancer varian two main report
segment oncolog system total revenu proton therapy/oth
total revenu januari spin-off imag compon busi
complet began regular way trade nasdaq global select
revenu
